Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets NEW HAVEN, Conn. and Monmouth Junction New Jersey, November 21, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and...
CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia -Phase 1/2 trial in β-thalassemia expected to begin in 2018- ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) — CRISPR...
Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma – First ACTR Combination Therapy Under Unum’s Collaboration with Seattle Genetics –...
Baylor Scott & White Health Selects Kyruus’ Solutions to Enhance Provider Data Management and Patient Access Leading Texas Health System to Leverage the KyruusOne™ Platform and ProviderMatch APIs to Create a Comprehensive Provider Directory and Improve Access to...
Mercy Health and Kyruus Forge Strategic Partnership to Further Enterprise-Wide Patient Access by Kyruus, on Feb 17, 2017 9:20:00 AM BOSTON, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that Mercy Health (based...
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium Data shows robust degradation of androgen receptor in vitro and in vivo NEW HAVEN, Conn., February 17, 2017 – Arvinas LLC, a private biotechnology...
Recent Comments